hyoscyamine has been researched along with nevirapine in 2 studies
Studies (hyoscyamine) | Trials (hyoscyamine) | Recent Studies (post-2010) (hyoscyamine) | Studies (nevirapine) | Trials (nevirapine) | Recent Studies (post-2010) (nevirapine) |
---|---|---|---|---|---|
99 | 1 | 55 | 3,212 | 509 | 1,108 |
Protein | Taxonomy | hyoscyamine (IC50) | nevirapine (IC50) |
---|---|---|---|
Chain B, Hiv-1 Reverse Transcriptase | Human immunodeficiency virus 1 | 0.08 | |
Chain A, Hiv-1 Reverse Transcriptase | Human immunodeficiency virus 1 | 0.08 | |
Chain A, Hiv-1 Reverse Transcriptase | Human immunodeficiency virus 1 | 0.08 | |
Chain A, Hiv-1 Reverse Transcriptase | Human immunodeficiency virus 1 | 0.08 | |
Chain B, Hiv-1 Reverse Transcriptase | Human immunodeficiency virus 1 | 0.08 | |
Chain A, Reverse transcriptase/ribonuclease H | Human immunodeficiency virus 1 | 1.165 | |
Prothrombin | Bos taurus (cattle) | 1.15 | |
Gag-Pol polyprotein | Human immunodeficiency virus type 1 BH10 | 1.4504 | |
Gag-Pol polyprotein | Human immunodeficiency virus type 2 (ISOLATE ROD) | 2.05 | |
Gag-Pol polyprotein | HIV-1 M:B_HXB2R | 1.4353 | |
Imidazoleglycerol-phosphate dehydratase | Saccharomyces cerevisiae S288C | 1.7 | |
Cytochrome P450 3A4 | Homo sapiens (human) | 0.181 | |
Cytochrome P450 2C9 | Homo sapiens (human) | 0.181 | |
Gag-Pol polyprotein | Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) | 0.69 | |
Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.7 | |
Microsomal triglyceride transfer protein large subunit | Homo sapiens (human) | 5.75 | |
Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | 0.18 | |
Reverse transcriptase/RNaseH | Human immunodeficiency virus 1 | 2.071 | |
Protease | Human immunodeficiency virus 1 | 0.101 | |
Reverse transcriptase | Human immunodeficiency virus 1 | 3.995 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
2 other study(ies) available for hyoscyamine and nevirapine
Article | Year |
---|---|
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |